Non-invasive proteomics-thinking about personalized breast cancer screening and treatment

EPMA Journal

Volumn 1, Issue 3, 2010, Pages 413-420

  Debald, Manuel ^a   Wolfgarten, Matthias ^a   Walgenbach Brünagel, Gisela ^a   Kuhn, Walther ^a   Braun, Michael ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Breast cancer; Personalized screening; Personalized treatment; Proteomics

Indexed keywords

ANTHRACYCLINE; APOLIPOPROTEIN C1; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 13; BRADYKININ; FIBRINOGEN; NUCLEAR MATRIX PROTEIN; PREALBUMIN; TAXANE DERIVATIVE;

BREAST CANCER; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RESEARCH; CANCER RISK; CANCER SCREENING; CANCER SUSCEPTIBILITY; DISTANT METASTASIS; HUMAN; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NIPPLE ASPIRATION; NON INVASIVE PROCEDURE; ONCOGENE; PERSONALIZED MEDICINE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEOMICS; RECURRENCE RISK; RECURRENT CANCER; REVIEW; SALIVA ANALYSIS; TUMOR GENE; TUMOR SUPPRESSOR GENE; TWO DIMENSIONAL GEL ELECTROPHORESIS;

EID: 79953053007     PISSN: 18785077     EISSN: 18785085     Source Type: Journal    
DOI: 10.1007/s13167-010-0039-9     Document Type: Review

References (80)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009; 59: 225-49.
2. Smith RA, Cokkinides V, Brooks D, Saslow D, Brawley OW. Cancer screening in the United States, 2010: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin. 2010; 60: 99-119.
3. Arriagada R, Rutqvist LE, Johansson H, Kramar A, Rotstein S. Predicting distant dissemination in patients with early breast cancer. Acta Oncol. 2008; 47: 1113-21.
4. Cianfrocca M, Goldstein LJ. Prognostic and predictive factors in early-stage breast cancer. Oncologist. 2004; 9: 606-16.
5. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007; 25: 5287-312.
6. Mommers EC, van Diest PJ, Leonhart AM, Meijer CJ, Baak JP. Balance of cell proliferation and apoptosis in breast carcinogenesis. Breast Cancer Res Treat. 1999; 58: 163-9.
7. Reis-Filho JS, Lakhani SR. The diagnosis and management of pre-invasive breast disease: genetic alterations in pre-invasive lesions. Breast Cancer Res. 2003; 5: 313-9.
8. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994; 266: 66-71.
9. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002; 415: 530-6.
10. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet. 2005; 365: 671-9.
11. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995; 378: 789-92.
12. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998; 62: 676-89.
13. Foster C, Evans DG, Eeles R, Eccles D, Ashley S, Brooks L, et al. Predictive testing for BRCA1/2: attributes, risk perception and management in a multi-centre clinical cohort. Br J Cancer. 2002; 86: 1209-16.
14. Michelsen TM, Dorum A, Dahl AA. A controlled study of mental distress and somatic complaints after risk-reducing salpingo-oophorectomy in women at risk for hereditary breast ovarian cancer. Gynecol Oncol. 2009; 113: 128-33.
15. van Oostrom I, Meijers-Heijboer H, Lodder LN, Duivenvoorden HJ, van Gool AR, Seynaeve C, et al. Long-term psychological impact of carrying a BRCA1/2 mutation and prophylactic surgery: a 5-year follow-up study. J Clin Oncol. 2003; 21: 3867-74.
16. Banks RE, Dunn MJ, Hochstrasser DF, Sanchez JC, Blackstock W, Pappin DJ, et al. Proteomics: new perspectives, new biomedical opportunities. Lancet. 2000; 356: 1749-56.
17. Azad NS, Rasool N, Annunziata CM, Minasian L, Whiteley G, Kohn EC. Proteomics in clinical trials and practice: present uses and future promise. Mol Cell Proteomics. 2006; 5: 1819-29.
18. Aebersold R, Anderson L, Caprioli R, Druker B, Hartwell L, Smith R. Perspective: a program to improve protein biomarker discovery for cancer. J Proteome Res. 2005; 4: 1104-9.
19. Dove A. Proteomics: translating genomics into products? Nat Biotechnol. 1999; 17: 233-6.
20. Hondermarck H, Vercoutter-Edouart AS, Revillion F, Lemoine J, el-Yazidi-Belkoura I, Nurcombe V, et al. Proteomics of breast cancer for marker discovery and signal pathway profiling. Proteomics. 2001; 1: 1216-32.
21. Engwegen JY, Gast MC, Schellens JH, Beijnen JH. Clinical proteomics: searching for better tumour markers with SELDI-TOF mass spectrometry. Trends Pharmacol Sci. 2006; 27: 251-9.
22. Hanash SM, Pitteri SJ, Faca VM. Mining the plasma proteome for cancer biomarkers. Nature. 2008; 452: 571-9.
23. Conrads TP, Zhou M, Petricoin III EF, Liotta L, Veenstra TD. Cancer diagnosis using proteomic patterns. Expert Rev Mol Diagn. 2003; 3: 411-20.
24. Callesen AK, Vach W, Jorgensen PE, Cold S, Tan Q, Depont CR, et al. Combined experimental and statistical strategy for mass spectrometry based serum protein profiling for diagnosis of breast cancer: a case-control study. J Proteome Res. 2008; 7: 1419-26.
25. De Noo ME, Deelder A, van der Werff M, Ozalp A, Mertens B, Tollenaar R. MALDI-TOF serum protein profiling for the detection of breast cancer. Onkologie. 2006; 29: 501-6.
26. Hu Y, Zhang S, Yu J, Liu J, Zheng S. SELDI-TOF-MS: the proteomics and bioinformatics approaches in the diagnosis of breast cancer. Breast. 2005; 14: 250-5.
27. Shin S, Cazares L, Schneider H, Mitchell S, Laronga C, Semmes OJ, et al. Serum biomarkers to differentiate benign and malignant mammographic lesions. J Am Coll Surg. 2007; 204: 1065-71.
28. Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem. 2002; 48: 1296-304.
29. Li J, Orlandi R, White CN, Rosenzweig J, Zhao J, Seregni E, et al. Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry. Clin Chem. 2005; 51: 2229-35.
30. Mathelin C, Cromer A, Wendling C, Tomasetto C, Rio MC. Serum biomarkers for detection of breast cancers: a prospective study. Breast Cancer Res Treat. 2006; 96: 83-90.
31. van Winden AW, Gast MC, Beijnen JH, Rutgers EJ, Grobbee DE, Peeters PH, et al. Validation of previously identified serum biomarkers for breast cancer with SELDI-TOF MS: a case control study. BMC Med Genomics. 2009; 2: 4.
32. Fung ET, Yip TT, Lomas L, Wang Z, Yip C, Meng XY, et al. Classification of cancer types by measuring variants of host response proteins using SELDI serum assays. Int J Cancer. 2005; 115: 783-9.
33. Song J, Patel M, Rosenzweig CN, Chan-Li Y, Sokoll LJ, Fung ET, et al. Quantification of fragments of human serum inter-alpha-trypsin inhibitor heavy chain 4 by a surface-enhanced laser desorption/ionization-based immunoassay. Clin Chem. 2006; 52: 1045-53.
34. Villanueva J, Shaffer DR, Philip J, Chaparro CA, Erdjument-Bromage H, Olshen AB, et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest. 2006; 116: 271-84.
35. Fan Y, Wang J, Yang Y, Liu Q, Fan Y, Yu J, Zheng S, Li M, Wang J. Detection and identification of potential biomarkers of breast cancer. J Cancer Res Clin Oncol. 2010 (Epub ahead of print).
36. Braun M, Fountoulakis M, Papadopoulou A, Vougas K, Seidel I, Holler T, et al. Down-regulation of microfilamental network-associated proteins in leukocytes of breast cancer patients: potential application to predictive diagnosis. Cancer Genomics Proteomics. 2009; 6: 31-40.
37. Brunagel G, Vietmeier BN, Bauer AJ, Schoen RE, Getzenberg RH. Identification of nuclear matrix protein alterations associated with human colon cancer. Cancer Res. 2002; 62: 2437-42.
38. Getzenberg RH, Pienta KJ, Huang EY, Coffey DS. Identification of nuclear matrix proteins in the cancer and normal rat prostate. Cancer Res. 1991; 51: 6514-20.
39. Getzenberg RH, Konety BR, Oeler TA, Quigley MM, Hakam A, Becich MJ, et al. Bladder cancer-associated nuclear matrix proteins. Cancer Res. 1996; 56: 1690-4.
40. Konety BR, Nangia AK, Nguyen TS, Veitmeier BN, Dhir R, Acierno JS, et al. Identification of nuclear matrix protein alterations associated with renal cell carcinoma. J Urol. 1998; 159: 1359-63.
41. Paul B, Dhir R, Landsittel D, Hitchens MR, Getzenberg RH. Detection of prostate cancer with a blood-based assay for early prostate cancer antigen. Cancer Res. 2005; 65: 4097-100.
42. van Le TS, Miller R, Barder T, Babjuk M, Potter DM, Getzenberg RH. Highly specific urine-based marker of bladder cancer. Urology. 2005; 66: 1256-60.
43. Walgenbach-Brunagel G, Burger B, Leman ES, Walgenbach KJ, Tolba R, Heukamp L, et al. The use of a colon cancer associated nuclear antigen CCSA-2 for the blood based detection of colon cancer. J Cell Biochem. 2008; 104: 286-94.
44. Luftner D, Possinger K. Nuclear matrix proteins as biomarkers for breast cancer. Expert Rev Mol Diagn. 2002; 2: 23-31.
45. Sauter ER, Shan S, Hewett JE, Speckman P, Du Bois GC. Proteomic analysis of nipple aspirate fluid using SELDI-TOF-MS. Int J Cancer. 2005; 114: 791-6.
46. Pawlik TM, Fritsche H, Coombes KR, Xiao L, Krishnamurthy S, Hunt KK, et al. Significant differences in nipple aspirate fluid protein expression between healthy women and those with breast cancer demonstrated by time-of-flight mass spectrometry. Breast Cancer Res Treat. 2005; 89: 149-57.
47. Noble JL, Dua RS, Coulton GR, Isacke CM, Gui GP. A comparative proteinomic analysis of nipple aspiration fluid from healthy women and women with breast cancer. Eur J Cancer. 2007; 43: 2315-20.
48. Alexander H, Stegner AL, Wagner-Mann C, Du Bois GC, Alexander S, Sauter ER. Proteomic analysis to identify breast cancer biomarkers in nipple aspirate fluid. Clin Cancer Res. 2004; 10: 7500-10.
49. Suijkerbuijk KP, van der Wall E, van Diest PJ. Oxytocin: bringing magic into nipple aspiration. Ann Oncol. 2007; 18: 1743-4.
50. Streckfus C, Bigler L, Dellinger T, Pfeifer M, Rose A, Thigpen JT. CA 15-3 and c-erbB-2 presence in the saliva of women. Clin Oral Investig. 1999; 3: 138-43.
51. Streckfus CF, Bigler LR, Zwick M. The use of surface-enhanced laser desorption/ionization time-of-flight mass spectrometry to detect putative breast cancer markers in saliva: a feasibility study. J Oral Pathol Med. 2006; 35: 292-300.
52. Streckfus CF, Mayorga-Wark O, Arreola D, Edwards C, Bigler L, Dubinsky WP. Breast cancer related proteins are present in saliva and are modulated secondary to ductal carcinoma in situ of the breast. Cancer Investig. 2008; 26: 159-67.
53. Coldman A, Phillips N, Warren L, Kan L. Breast cancer mortality after screening mammography in British Columbia women. Int J Cancer. 2007; 120: 1076-80.
54. Tabar L, Yen MF, Vitak B, Chen HH, Smith RA, Duffy SW. Mammography service screening and mortality in breast cancer patients: 20-year follow-up before and after introduction of screening. Lancet. 2003; 361: 1405-10.
55. Jorgensen KJ, Gotzsche PC. Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends. BMJ. 2009; 339: b2587.
56. Buist DS, Porter PL, Lehman C, Taplin SH, White E. Factors contributing to mammography failure in women aged 40-49 years. J Natl Cancer Inst. 2004; 96: 1432-40.
57. Schopper D, de Wolf C. How effective are breast cancer screening programmes by mammography? Review of the current evidence. Eur J Cancer. 2009; 45: 1916-23.
58. Brekelmans CT, van Gorp JM, Peeters PH, Collette HJ. Histopathology and growth rate of interval breast carcinoma. Characterization of different subgroups. Cancer. 1996; 78: 1220-8.
59. Braun M, Fountoulakis M, Yeghiazaryan K, Schild HH, Kuhn W, Golubnitschaja O. How realistic are non-invasive approaches in breast cancer prediction? In: Golubnitschaja O, editor. Predictive diagnostics and personalized treatment: dream or reality? New York: Nova Science Publishers; 2009.
60. Hanash S. Integrated global profiling of cancer. Nat Rev Cancer. 2004; 4: 638-44.
61. Classen S, Muth C, Debey-Pascher S, Eggle D, Beyer M, Mallmann MR, et al. Application of T cell-based transcriptomics to identify three candidate biomarkers for monitoring anti-TGFbetaR therapy. Pharmacogenet Genomics. 2010; 20: 147-56.
62. Yeghiazaryan K, Braun M, Mangion J, Mamlouk S, Schild HH, Golubnitschaja O. Are side-effects of irradiation predictable for treatment of breast cancer patients? In: Golubnitschaja O, editor. Predictive diagnostics and personalized treatment: dream or reality? New York: Nova Science Publishers; 2009.
63. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24, 740 breast cancer cases. Cancer. 1989; 63: 181-7.
64. Galea MH, Blamey RW, Elston CE, Ellis IO. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat. 1992; 22: 207-19.
65. Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou JY, Ma Y, et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol. 1997; 15: 2894-904.
66. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002; 347: 1999-2009.
67. Cronin M, Pho M, Dutta D, Stephans JC, Shak S, Kiefer MC, et al. Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. Am J Pathol. 2004; 164: 35-42.
68. Foekens JA, Atkins D, Zhang Y, Sweep FC, Harbeck N, Paradiso A, et al. Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J Clin Oncol. 2006; 24: 1665-71.
69. Duffy MJ. Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence studies. Clin Chem. 2002; 48: 1194-7.
70. Harbeck N, Kates RE, Look MP, Meijer-van Gelder ME, Klijn JG, Kruger A. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424). Cancer Res. 2002; 62: 4617-22.
71. Harbeck N, Schmitt M, Kates RE, Kiechle M, Zemzoum I, Janicke F, et al. Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts. Clin Breast Cancer. 2002; 3: 196-200.
72. Janicke F, Prechtl A, Thomssen C, Harbeck N, Meisner C, Untch M, et al. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst. 2001; 93: 913-20.
73. Hayes DF, Thor AD, Dressler LG, Weaver D, Edgerton S, Cowan D, et al. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med. 2007; 357: 1496-506.
74. Paik S, Bryant J, Park C, Fisher B, Tan-Chiu E, Hyams D, et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst. 1998; 90: 1361-70.
75. Thor AD, Berry DA, Budman DR, Muss HB, Kute T, Henderson IC, et al. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst. 1998; 90: 1346-60.
76. Burgess DJ, Doles J, Zender L, Xue W, Ma B, McCombie WR, et al. Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc Natl Acad Sci USA. 2008; 105: 9053-8.
77. Jarvinen TA, Tanner M, Rantanen V, Barlund M, Borg A, Grenman S, et al. Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol. 2000; 156: 839-47.
78. Rouzier R, Rajan R, Wagner P, Hess KR, Gold DL, Stec J, et al. Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci USA. 2005; 102: 8315-20.
79. Pusztai L. Markers predicting clinical benefit in breast cancer from microtubule-targeting agents. Ann Oncol. 2007; 18 Suppl 12: xii15-20.
80. Andre F, Hatzis C, Anderson K, Sotiriou C, Mazouni C, Mejia J, et al. Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer. Clin Cancer Res. 2007; 13: 2061-7.